We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Clinical Trial Medical-Image Collect-and-Hold System Centralizes Imaging Data

By LabMedica International staff writers
Posted on 20 Aug 2009
Print article
A new image management solution has been designed to collect and hold medical images in clinical trials, called iMAS (image management archive system). The iMAS is a cost-effective option for clinical trial sponsors to centralize the collection of the large imaging data sets frequently utilized in clinical trials, while giving them accessibility and secure storage, with minimal investment.

The system was developed by M2S, Inc. (West Lebanon, NH, USA), a global provider of image management services for biopharmaceutical and medical device clinical trials. M2S offers cost-effective medical image management solution for clinical trial sponsors.

"Clinical trial sponsors are facing extraordinary cost pressures in the current economy,” said Wes Chapman, CEO of M2S. "With less time needed for setup, decreased trial complexity, and reduced documentation requirements, an M2S iMAS trial is typically only 20% of the cost of a full clinical trial. This option gives trial sponsors the control and flexibility to adjust a trial and add a blinded radiological review at any point, while simultaneously containing costs.”

While many clinical trials continue to incorporate imaging data for surrogate endpoints, it is not always clear whether image data review and submission will be necessary. However, potentially valuable and expensive imaging data can and probably should still be collected. Sponsors may want to consider using those images for a later submission, subsequent trials or for patient registries, and the risk, cost, and effort of retrospectively collecting images can exceed that of prospective medical image collection.

M2S will customize the iMAS product based on service levels needed for a particular clinical trial--including consultation, project management, and query management. Real-time, web-based reports allow sponsors to see both the status of data gathered as well as access the data anytime, anywhere.

M2S provides medical image data management services across the healthcare continuum based on best-in-class technology and continuous quality improvement processes. M2S clinical trial image-management services include protocol development, electronic image collection, independent review, archive, and real-time web-based data access. M2S clinical data registries provide long-term evaluation of treatment outcomes, benefits, and cost.

Related Links:
M2S

New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test
New
Hepato Fibrosis Assays
Hepato Fibrosis Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The AI program analyzes a microscopy image from a tumor biopsy and determines what genes are likely turned on and off in the cells it contains (Photo courtesy of Olivier Gevaert/Stanford Medicine)

AI Tool ‘Sees’ Cancer Gene Signatures in Biopsy Images

To assess the type and severity of cancer, pathologists typically examine thin slices of a tumor biopsy under a microscope. However, to understand the genomic alterations driving the tumor's growth, scientists... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.